Japan approves pioneering iPS-based therapies for Parkinson’s and heart failure

Japan grants conditional, time-limited approvals for Amchepry (Parkinson’s) and ReHeart (heart failure), two iPS-cell therapies that could reach patients within months and mark the first commercially available iPS-based medical products, based on small trials showing safety and some symptom improvements with ongoing monitoring.